

# **Market Announcement**

20 July 2020

# Prescient Therapeutics Limited (ASX: PTX) - Trading Halt

## **Description**

The securities of Prescient Therapeutics Limited ('PTX') will be placed in trading halt at the request of PTX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 22 July 2020 or when the announcement is released to the market.

## **Issued by**

#### **Melissa Kostopoulos**

Compliance Adviser, Listings Compliance (Melbourne)



20 July 2020

Melissa Kostopulos ASX Limited Level 4, North Tower 525 Collins Street MELBOURNE VIC 3000

(By email: melissa.kostopoulos@asx.com.au)

#### **REQUEST FOR TRADING HALT**

Prescient Therapeutics Limited (ASX: **PTX**) (the **Company**) requests an immediate halt to the trading of the Company's securities (ASX: PTX) quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending an announcement by the Company to the market regarding a collaboration announcement.

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- 1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose above.
- 2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Wednesday, 22 July 2020, or when the announcement regarding the stated purpose is released to the market.
- 3. The Company expects to make the announcement to the market before the commencement of normal trading on Wednesday, 22 July 2020.
- 4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely,

**Prescient Therapeutics Limited** 

Melanie Leydin Company Secretary